Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis.
Four patients with cryptococcal meningitis were successfully treated with liposomal amphotericin B prepared at our institute using Soya phosphatidylcholine and cholesterol. In one patient, response with 1 mg/kg/day treatment was poor. However, on increasing the dose to 2 mg/kg/day, a good response was observed with CSF becoming negative for Cryptococcus neoformans after seven days of this enhanced dose. L-AMP-LRC-1 was found to be well tolerated and a major advantage was observed in two renal transplant patients in whom it could be given safely.
Kotwani
R N
RN
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Parel, Mumbai.
Gokhale
P C
PC
Bodhe
P V
PV
Kirodian
B G
BG
Kshirsagar
N A
NA
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D008081:Liposomes; D016919:Meningitis, Cryptococcal / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B